XDG3.DE
Xtrackers MSCI Global SDG 3 Good Health UCITS ETF 1C
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
€ 21.0 M
ASSETS UNDER MGMT
35 bp
EXPENSES
Fund Basics
| Inception date | Jan 18, 2023 |
| Regulation | UCITS |
| Fund Website | link... |
| Distributions | |
| Currency | EUR |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| ELI LILLY & CO | 5.0 % |
| NOVO NORDISK A/S-B | 4.9 % |
| VERTEX PHARMACEUTICALS INC | 4.8 % |
| MERCK & CO. INC. | 4.8 % |
| ABBVIE INC | 4.6 % |
| BRISTOL-MYERS SQUIBB CO | 4.6 % |
| AMGEN INC | 4.6 % |
| ASTRAZENECA PLC | 4.5 % |
| GILEAD SCIENCES INC | 4.3 % |
| STRYKER CORP | 4.2 % |
Constituent Breakdown
| Number of holdings | 111 |
| Herfindahl-Hirschman Index | 312 |
| Wgt avg mkt cap (mns) | $174,930 |
| Large cap (>$10bn) | 93.5% |
| Mid cap ($2-10bn) | 4.2% |
| Small cap (<$2bn) | 1.0% |
| Developed mkts. | 97.4% |
| Emerging mkts. | 1.2% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 70.4 % |
 |
BRITAIN | 7.5 % |
 |
DENMARK | 5.5 % |
 |
JAPAN | 3.5 % |
 |
FRANCE | 3.3 % |
 |
IRELAND | 2.7 % |
 |
NETHERLANDS | 2.1 % |
 |
CHINA | 1.1 % |
 |
AUSTRALIA | 1.0 % |
 |
SWEDEN | 0.8 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -6.7% | 2.3% | -1.4% | 2.4% | -- | -- | -- | 1.9% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | -- | 0.0% |
| Total Returns | -6.7% | 2.3% | -1.4% | 2.4% | -- | -- | -- | 1.9% | Ann. Volatility | 15.2% | 26.0% | 21.3% | 18.3% | -- | -- | -- | 17.7% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.32 | 2% |
| MSCI EAFE | 0.25 | 2% |
| MSCI Emg Mkts | 0.13 | 1% |
Liquidity Measures
| Avg. volume (000) | 0 |
| ADV traded (mns) | $0 |
| Turnover | 0.0% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $29.85 |
| Relative strength (RSI) | 47 |
| MACD/Signal | -0.04/-0.18 |
| Bollinger Bands (Upper/Lower) | $30.24/$28.68 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. XDG3.DE |
Expenses vs. XDG3.DE |
ALTAR Score™ vs. XDG3.DE |
|---|---|---|---|---|
| WELG.DE | Amundi S&P World Health Care Screened UCITS ETF Dist | 53.3% | -17 bp | +0.1% |
| WELS.DE | Amundi S&P World Health Care Screened UCITS ETF Acc | 53.3% | -17 bp | +0.2% |
| XDWH.DE | Xtrackers MSCI World Health Care UCITS ETF 1C | 47.4% | -10 bp | +0.4% |
| XUHL.DE | Xtrackers MSCI USA Health Care UCITS ETF 1C | 46.4% | -23 bp | +0.5% |
| XUHC.DE | Xtrackers MSCI USA Health Care UCITS ETF 1D | 46.4% | -23 bp | +0.4% |
| IUHC.L | iShares S&P 500 Health Care Sector UCITS ETF | 43.6% | -20 bp | +0.6% |
| IUHE.AS | iShares S&P 500 Health Care Sector UCITS ETF | 43.6% | -17 bp | +0.7% |
| WHCA.L | iShares MSCI World Health Care Sector Advanced UCITS ETF | 41.1% | -17 bp | +0.0% |
| WHCS.AS | iShares MSCI World Health Care Sector Advanced UCITS ETF | 41.1% | -17 bp | +0.2% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 27.4% | +5 bp | -4.1% |
Risk and Returns: XDG3.DE vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (EUR)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/3/2026
Peer Group Comparison
Sample data. Subscribe for access.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.7%
ALTAR SCORE™
83rd
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 727 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. XDG3.DE's ALTAR Score™ is approximately 0.9 standard
deviations above the category average. This places XDG3.DE in the 83rd percentile
among funds in the category.
Sell-Side Consensus
€37.93
PRICE TARGET
+29.9%
UPSIDE